128 related articles for article (PubMed ID: 17237269)
61. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G; Chardès T; Gaborit N; Mollevi C; Leconet W; Robert B; Radosevic-Robin N; Penault-Llorca F; Gongora C; Colombo PE; Lazrek Y; Bras-Goncalves R; Savina A; Azria D; Bazin H; Pèlegrin A; Larbouret C
Oncotarget; 2014 Aug; 5(16):7138-48. PubMed ID: 25216528
[TBL] [Abstract][Full Text] [Related]
62. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
[TBL] [Abstract][Full Text] [Related]
63. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G
Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183
[TBL] [Abstract][Full Text] [Related]
64. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
[TBL] [Abstract][Full Text] [Related]
65. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
66. Effects of HER2-binding affibody molecules on intracellular signaling pathways.
Ekerljung L; Steffen AC; Carlsson J; Lennartsson J
Tumour Biol; 2006; 27(4):201-10. PubMed ID: 16651854
[TBL] [Abstract][Full Text] [Related]
67. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
68. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
69. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3.
Sak MM; Szymanska M; Bertelsen V; Hasmann M; Madshus IH; Stang E
Carcinogenesis; 2013 Sep; 34(9):2031-8. PubMed ID: 23698633
[TBL] [Abstract][Full Text] [Related]
70. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
71. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.
Naderi A; Hughes-Davies L
Neoplasia; 2008 Jun; 10(6):542-8. PubMed ID: 18516291
[TBL] [Abstract][Full Text] [Related]
72. Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.
Lebedeva G; Sorokin A; Faratian D; Mullen P; Goltsov A; Langdon SP; Harrison DJ; Goryanin I
Eur J Pharm Sci; 2012 Jul; 46(4):244-58. PubMed ID: 22085636
[TBL] [Abstract][Full Text] [Related]
73. New insights on the role of hormonal therapy in ovarian cancer.
Simpkins F; Garcia-Soto A; Slingerland J
Steroids; 2013 Jun; 78(6):530-7. PubMed ID: 23402742
[TBL] [Abstract][Full Text] [Related]
74. Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.
Ribeiro JR; Freiman RN
J Steroid Biochem Mol Biol; 2014 Sep; 143():160-73. PubMed ID: 24565562
[TBL] [Abstract][Full Text] [Related]
75. Erythropoietin receptor in ovarian cancer cells - Letter.
Swift SE; Elliott S; Sinclair AM; Begley CG
Mol Cancer Ther; 2010 Apr; 9(4):1070-1; author reply 1071. PubMed ID: 20371727
[No Abstract] [Full Text] [Related]
76. A simplified culture system to examine soluble factor interactions between mammalian cells.
Carroll MJ; Stopfer LE; Kreeger PK
Chem Commun (Camb); 2014 May; 50(40):5279-81. PubMed ID: 24233400
[TBL] [Abstract][Full Text] [Related]
77. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
78. Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
Zhang S; Balch C; Chan MW; Lai HC; Matei D; Schilder JM; Yan PS; Huang TH; Nephew KP
Cancer Res; 2008 Jun; 68(11):4311-20. PubMed ID: 18519691
[TBL] [Abstract][Full Text] [Related]
79. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y; Erfani S; Schweer D; de Gouvea R; Qadir J; Shi J; Cheng K; Wu D; Craven R; Wu Y; Olivier T; Baldwin LA; Zhou B; Zhou Y; Zhao W; Yang BB; Ueland FR; Yang XH
Mol Ther Oncolytics; 2023 Mar; 28():293-306. PubMed ID: 36911068
[TBL] [Abstract][Full Text] [Related]
80. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in
Fang X; Mou H; Ying X; Hou X; Wang L; Wu Y; Yan N; Guo L; Liao Q
Front Oncol; 2022; 12():1024677. PubMed ID: 36620566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
